Methods of treating and detecting cancer using viruses
The invention provides a method of treating cancer in a mammal comprising administering to the mammal an effective amount of virus, particularly Newcastle Disease Virus or other Paramyxovirus. The invention also provides a method of treating cancer in a mammal comprising administering such viruses to the mammal in combination with another agent such as a chemotherapeutic compound, immunoadjuvant, cytokine, or immunosuppressive agent. The invention further provides a method of detecting cancer cells in a mammal using Paramyxovirus as an imaging agent and as an indicator of cancer cell growth in the mammal. The invention further provides genetically engineered Paramyxoviruses, and kits containing the viral compositions disclosed by the invention.
1. A method of treating cancer in a mammal having a tumor comprising administering intravenously to said mammal more than one dose of a composition comprising live Newcastle Disease Virus in an amount sufficient to cause tumor regression, wherein said composition is essentially free of allantoic fluid.
2. A method of treating cancer in a mammal having a tumor comprising administering to said mammal more than one dose of a pharmaceutical composition comprising live purified Newcastle Disease Virus in an amount sufficient to cause tumor regression, wherein said live purified Newcastle Disease Virus is administered systemically not directly at the tumor site.
3. The method of claim 1 or 2 , wherein said tumor is selected from the group consisting of lung carcinoma, breast carcinoma, prostate carcinoma, endometrial carcinoma, ovarian carcinoma, bladder carcinoma, Wilm's tumor, fibrosarcoma, osteosarcoma, synovial sarcoma and glioblastoma.
4. The method of claim 1 or 2 , wherein said tumor is colon adenocarcinoma.
5. The method of claim 1 or 2 , wherein said tumor is melanoma.
6. The method of claim 1 or 2 , wherein said tumor is neuroblastoma.
7. The method of claim 1 or 2 , wherein said Newcastle Disease Virus is strain Mass MK107.
8. The method of claim 1 or 2 , wherein said Newcastle Disease Virus is strain 73-T.
9. The method of claim 1 or 2 , wherein the amount of Newcastle Disease Virus administered is about 4×10 10 to 4×10 12 PFU/kg.
10. The method of claim 1 or 2 , wherein the Newcastle Disease Virus is administered in an amount of 10 8 PFU.
11. The method of claim 1 or 2 , further comprising administering a chemotherapeutic agent.
12. The method of claim 11 , wherein the chemotherapeutic agent is selected from the group consisting of thiotepa, busulfan, cyclophosphamide, methotrexate, cytarabine, bleomycin, cisplatin, doxorubicin, melphalan, mercaptopurine, vinblastine, paclitaxel and retinoic acid.
13. The method of claim 11 , wherein the chemotherapeutic agent is 5-fluorouracil.
14. The method of claim 1 or 2 , further comprising administering an immunosuppressive agent.
15. The method of claim 14 , wherein said immunosuppressive agent is a corticosteroid.
16. The method of claim 1 or 2 , further comprising administering a cytotoxic or cytostatic agent.
17. The method of claim 16 , wherein said cytotoxic or cytostatic agent is an antibody.
18. The method of claim 16 , wherein said cytotoxic or cytostatic agent is a cytokine.
19. The method of claim 1 or 2 , wherein said Newcastle Disease Virus is purified from cell culture.
20. The method of claim 1 or 2 , wherein said tumor is cervical carcinoma.
21. The method of claim 1 or 2 , wherein said composition also comprises a pharmaceutically acceptable carrier.
22. The method of claim 1 or 2 , wherein said tumor is a human tumor.
23. The method of claim 1 or 2 , wherein said tumor is greater than 0.6 cm in diameter.
24. The method of claim 1 or 2 , wherein said tumor is a metastatic tumor.
25. The method of claim 1 or 2 , further comprising administering radiation.